At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Angiotensin Converting Enzyme Inhibitor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Angiotensin Converting Enzyme Inhibition During and After Cardiopulmonary Bypass in Infants and Children With Congenital Heart Defects
In Brief
A clinical study evaluating Angiotensin Converting Enzyme Inhibitor and No ACE Inhibitor for Congenital Heart Disease. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether ACE inhibitors alter the fibrinolytic, inflammatory, and hemodynamic response to cardiopulmonary bypass in infants and children with congenital heart disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongenital Heart Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedFeb 2009
Primary CompletionJul 2010
TodayJul 2026
First PostedFeb 20, 2009
Enrollment StartSep 1, 2008
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.4 years ago
Interventions
Angiotensin Converting Enzyme Inhibitordrug
Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
No ACE Inhibitorother
Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery